10-K: Lumexa Imaging grows to $1.02B revenue, trims loss

Lumexa Imaging posted 7.8% revenue growth to $1.023B in 2025, narrowed its net loss to $47.1M, raised $427M in its December IPO, and refinanced debt while flagging material weaknesses in internal controls.

Summary

• Total revenue rose 7.8% year over year to $1,023.1 million for the year ended December 31, 2025 (2024: $948.9 million).
• Net loss improved to $47.1 million in 2025 from $94.1 million in 2024; loss before income taxes was $32.2 million.
• Adjusted EBITDA was $230.2 million with a 22.5% margin (2024: $200.8 million, 21.2% margin).
• Equity in earnings of unconsolidated affiliates was $72.1 million (2024: $71.5 million).
• Net patient service revenue totaled $802.7 million, including $36.0 million from related parties; management fee and other revenue totaled $220.4 million (including $200.8 million related party).
• Operating cash flow was $17.1 million (2024: $40.7 million); year-end cash was $58.8 million.
• Refinanced term loan to $825.0 million (SOFR + 3.00%) on December 17, 2025; $250.0 million revolver undrawn at year-end.
• Interest expense was $118.5 million (down from $136.0 million in 2024); recorded $13.5 million loss on extinguishment of debt related to refinancing.
• Completed an IPO of 25,000,000 shares at $18.50 on December 12, 2025, generating approximately $427 million in net proceeds; used $406.4 million to pay down prior term debt.
• System-wide revenue growth was 8.2%; consolidated revenue growth was 7.8%.
• As of year-end, operated 188 centers across 13 states (102 consolidated; 86 unconsolidated JVs); MRI/CT represented 52% of consolidated revenue and 63% of system-wide revenue.
• Consolidated outpatient same-center revenue up 7.7% (volume +5.4%, net revenue per scan +2.2%); professional same-practice revenue up 8.7% (volume +5.4%, net revenue per read +3.1%).
• Patient NPS of 91 and 97% overall patient satisfaction as of December 31, 2025; ~99% of services in-network with commercial payors.
• Maintained payor mix with 58% consolidated revenue from commercial payors and 29% from government programs.
• Identified continuing material weaknesses in internal control over financial reporting (ICFR) as of December 31, 2025 and outlined remediation plans.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a balanced update: revenue and margins improved and leverage terms strengthened post‑IPO, but cash generation was modest, interest expense remains high, and material control weaknesses persist.

Positives

• Revenue growth of 7.8% to $1.023 billion with improved net loss of $47.1 million (vs. $94.1 million in 2024).
• Adjusted EBITDA increased to $230.2 million with margin expansion to 22.5% (from 21.2%).
• Interest expense declined by $17.5 million year over year, aided by refinancing and lower rates.
• Successful IPO raised approximately $427 million in net proceeds; $406.4 million used to delever the balance sheet.
• Refinanced term loan ($825.0 million; SOFR + 3.00%) and secured a $250.0 million undrawn revolver, extending maturities (term loan to December 2032; revolver to December 2030).
• Same-center growth remained strong: consolidated outpatient +7.7% (volume +5.4%); professional services +8.7%.
• Expanded footprint to 188 centers across 13 states; opened 9 de novo centers during 2025.
• High patient satisfaction (NPS 91; 97% overall) and ~99% in-network footprint with commercial payors.
• Health system JVs continued to contribute: $72.1 million equity in earnings; two-year JV distributions slightly exceeded JV earnings.

Negatives

• Operating cash flow fell to $17.1 million from $40.7 million, reflecting timing of JV distributions and elevated operating/transaction costs.
• Material weaknesses in ICFR persist across multiple areas (control environment, revenue recognition controls, segregation of duties, and IT general controls).
• High leverage remains with $825.0 million term loan outstanding despite deleveraging; interest expense still significant at $118.5 million.
• Net loss remains ($47.1 million), and income tax provision of $14.9 million despite pre-tax loss.
• G&A rose 28.6% to $90.5 million, driven by IPO-related costs, IT investments, legal/professional fees, and stock-based compensation.

Risks

• Dependence on referrals from physicians and other healthcare providers to drive scan volumes.
• Fixed-cost structure amplifies impact of lower volume or unfavorable modality mix on profitability.
• Shortages of radiologists and technologists, wage inflation, and competition for staffing could raise labor costs and constrain capacity.
• Reliance on health system joint venture partners; inability to maintain or expand JV relationships could impair growth.
• Reductions in Medicare/Medicaid or commercial reimbursement rates, NSA implementation dynamics, and collection risks could harm revenue and margins.
• Competitive pressures from other diagnostic imaging companies, hospitals, physician practices, and teleradiology providers.
• Regulatory exposure (Anti-Kickback Statute, Stark Law, FCA, HIPAA/HITECH, NSA, state corporate practice/fee-splitting, CON laws, antitrust reviews) and potential penalties for noncompliance.
• Cybersecurity threats and data privacy risks; prior December 2021 breach led to settlements; ongoing exposure to evolving threat landscape.
• Operational and legal risks related to current and future use of AI, including potential misdiagnoses, regulatory constraints, and privacy concerns.
• Macroeconomic headwinds (inflation, recession risk) may reduce demand for non-emergent imaging and increase bad debt/uncompensated care.
• Technological change or disruptive diagnostics (e.g., blood-based screening) could reduce imaging demand or accelerate equipment obsolescence.
• Material weaknesses in internal control over financial reporting may lead to reporting risks until remediated.
• Debt covenants and leverage may limit financial flexibility; inability to refinance or service debt could have adverse effects.
• State and federal transaction review and antitrust scrutiny could limit M&A and JV expansion.
• Potential dilution associated with certain incentive units upon distributions or liquidation events at a holding entity.

Future Outlook

Management plans to drive above-market same-center growth, accelerate de novo development in existing and new MSAs, expand and add health system joint ventures, pursue disciplined acquisitions, and continue deploying third-party AI and enterprise technology (including ERP) to improve throughput, clinical quality, and back-office efficiency. The company expects continued demand tailwinds from advanced imaging utilization and payor preference for lower-cost outpatient sites, while monitoring reimbursement changes and labor market dynamics.

Management Comments

• Management believes its national outpatient platform, focus on advanced modalities, and presence in attractive MSAs support sustained growth.
• Management expects third-party AI deployment to reduce scan times, improve read efficiency and quality, and lower select costs (e.g., third‑party radiologist salaries were approximately $40 million in 2025).
• The company views health system joint ventures as a capital‑efficient growth avenue that diversifies revenue and expands patient access.
• Leadership plans to remediate material weaknesses by enhancing staffing, formalizing controls over revenue recognition, segregation of duties, and IT general controls, and implementing new technology platforms.

Industry Context

StockSavvy.ai notes that outpatient diagnostic imaging continues to gain share from hospital outpatient departments as payors steer patients to lower-cost settings. The U.S. diagnostic imaging services market grew at a mid-single digit CAGR pre-2025, with freestanding centers outpacing hospital sites. Advanced imaging (MRI/CT) is growing faster than routine imaging, supported by aging demographics and broader clinical indications. Key public peer RadNet emphasizes similar growth levers (advanced imaging, AI workflow, hospital partnerships), with typical adjusted EBITDA margins for scaled platforms in the high teens to low 20s, consistent with Lumexa’s 22.5% margin.

Comparison to Industry Standards

• Scale and footprint: With 188 centers across 13 states, Lumexa ranks among the largest U.S. outpatient imaging operators; RadNet (NASDAQ: RDNT) is the closest public comparator by center count and national reach.
• Margin profile: Lumexa’s 2025 Adjusted EBITDA margin of 22.5% is in line to slightly above typical high‑teens to low‑20s margins observed at scaled outpatient imaging peers, reflecting JV management fees and system‑wide operating leverage.
• Growth mix: System‑wide growth of 8.2% and consolidated growth of 7.8% compare favorably to the U.S. diagnostic imaging market’s mid‑single digit expansion; same‑center and professional services growth metrics suggest solid volume and pricing discipline.
• Capital structure: Post‑IPO and refinancing, Lumexa remains more leveraged than some peers, which can weigh on net income via interest expense; continuing deleveraging and cost of capital improvements would further align with best‑in‑class benchmarks.

Management Changes

Corporate Governance

Legal Proceedings

• Ordinary-course professional liability and regulatory inquiries; management does not expect a material adverse effect.
• December 2021 data breach resulted in certain settlements, including penalties to the New York Attorney General; no material cybersecurity incidents reported since.

Related Party Transactions

• Significant management fee and pass-through arrangements with unconsolidated health system joint ventures; related party management fee and other revenue totaled $200.8 million in 2025.
• Net patient service revenue from related parties was $36.0 million in 2025 (e.g., reads for JV centers and affiliated hospitals).
• Equity method investment in BTDI JV, LLP (49% ownership through affiliates); BTDI net income $122.8 million in 2025, with $56.6 million share of earnings recognized and substantial related party payables/receivables.
• Joinder to a Registration Rights Agreement with WCAS and others on December 12, 2025, granting demand and shelf registration rights and piggyback rights.

Stakeholder Impact

• Shareholders: IPO enhanced liquidity and deleveraging; anti-takeover and exclusive forum provisions provide governance stability but may limit change-in-control opportunities.
• Employees/Physicians: Continued investments in staffing, training (Technologist Advancement Academy), and AI/tech tools; competitive wage environment may persist.
• Customers/Patients: High satisfaction metrics (NPS 91); ~99% in-network coverage supports access and affordability versus HOPD sites.
• Health System Partners: JV model expands outpatient access, diversifies revenue streams, and leverages Lumexa’s operating scale.
• Creditors: Refinancing extended maturities and reduced spread; interest expense remains material but trending down.

Next Steps

• Continue de novo center development in targeted MSAs; typical initial capital ~$4.0 million per center with EBITDA ramp targets.
• Expand existing health system joint ventures and pursue new JV partnerships in untapped MSAs.
• Pursue disciplined acquisitions (targeting mid‑single to high‑single digit EBITDA multiples pre‑synergies) and integrate prior deals.
• Deploy and scale third‑party AI tools across clinical and back‑office workflows; continue ERP and technology platform implementations.
• Remediate identified material weaknesses in ICFR by enhancing staffing, formalizing revenue controls, segregation of duties, and IT general controls.
• Optimize capital structure and monitor refinancing opportunities to further reduce interest costs.

Key Dates

Recommendation

Improving revenue, margin expansion, and balance sheet progress post‑IPO support the story, but modest cash generation, ongoing material control weaknesses, and high though reduced leverage argue for patience. Execution on JV growth, de novos, AI efficiencies, and ICFR remediation are the next catalysts to shift conviction.

Keywords

Lumexa Imaging, diagnostic imaging, MRI, CT, IDTF, health system joint venture, Adjusted EBITDA, IPO, refinancing, Medicare reimbursement, NSA, AI in radiology, HIPAA, cybersecurity, RadNet, outpatient imaging centers